Agios Pharmaceuticals Insider Sells $102,047 in Stock

Insider Sarah Gheuens reduces position by 3.5% through planned sale to cover tax obligations

Apr. 7, 2026 at 8:36am

Got story updates? Submit your updates here. ›

An extreme close-up of a series of interlocking metal gears and machinery, conveying the heavy, industrial nature of the financial systems that power the pharmaceutical sector.An insider sale of Agios Pharmaceuticals stock highlights the complex financial mechanics underlying the biotech industry.Cambridge Today

Agios Pharmaceuticals (NASDAQ:AGIO) insider Sarah Gheuens sold 2,940 shares of the company's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71 for a total value of $102,047.40. The sale was made to cover tax withholding obligations related to the vesting of equity awards and was executed under a pre-arranged Rule 10b5-1 trading plan.

Why it matters

Insider transactions, especially sales, can provide insights into management's views on a company's prospects. However, planned sales to cover tax obligations are generally viewed as routine and neutral by investors, as they do not necessarily reflect a negative outlook.

The details

The sale by Sarah Gheuens represented a 3.53% decrease in her position. Following the transaction, Gheuens directly owned 80,277 shares in the company, valued at approximately $2.79 million. The sale was disclosed in a filing with the Securities and Exchange Commission.

  • The transaction occurred on Thursday, April 2nd, 2026.

The players

Sarah Gheuens

An insider at Agios Pharmaceuticals who sold 2,940 shares of the company's stock.

Agios Pharmaceuticals, Inc.

A biopharmaceutical company focused on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases.

Got photos? Submit your photos here. ›

What they’re saying

“The sale was executed under a pre-arranged Rule 10b5-1 trading plan.”

— Sarah Gheuens, Insider

The takeaway

Insider sales to cover tax obligations are common and generally viewed as routine by investors, as they do not necessarily reflect a negative outlook on the company's prospects. Agios Pharmaceuticals continues to focus on its pipeline of cancer and rare disease therapies targeting cellular metabolism.